Master Session: Ovarian Cancer
Chair(s)
Andreas Du Bois (Germany)Thomas J. Herzog (USA)Amit Oza (Canada)Isabella L. Ray-Coquard (France)Anil K. Sood (USA)
Moderated by Andreas Du Bois
Debate 1: Pro
Anil K. Sood (USA)
Debate 1: Con
Florian Heitz (Germany)
Moderated by Amit Oza
Potential impact on standard of care: Review of pending trials - Overview
Isabella L. Ray-Coquard (France)
Potential impact on standard of care: Review of pending trials - Analysis
Bradley J. Monk (USA)
PANEL 2: DEVELOPMENTAL THERAPEUTICS
Moderated by Isabelle Ray-Coquard (France)
Overcoming PARP resistance
Amit Oza (Canada)
Leveraging new pathways for ovarian cancer
Shannon N. Westin (USA)
Moderated by Anil Sood (USA)
HIPEC: A Critical Appraisal of Promises and Challenges
Kathleen N. Moore (USA)
Is it ready for primetime? Addressing the knowledge gaps in HIPEC data
Thomas J. Herzog (USA)
DEBATE 2: SECONDARY CYTOREDUCTION
Moderated by Thomas Herzog (USA)
Debate 2: Pro
Andreas Du Bois (Germany)
Debate 2: Con
Robert L. Coleman (USA)